Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
7.49
-0.11 (-1.45%)
Nov 28, 2025, 4:00 PM EST - Market closed
Cartesian Therapeutics Employees
Cartesian Therapeutics had 66 employees as of December 31, 2024. The number of employees increased by 28 or 73.68% compared to the previous year.
Employees
66
Change (1Y)
28
Growth (1Y)
73.68%
Revenue / Employee
$16,530
Profits / Employee
-$726,955
Market Cap
194.77M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 66 | 28 | 73.68% |
| Dec 31, 2023 | 38 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RNAC News
- 13 days ago - Cartesian: Maintaining Buy Rating For Expansion Of Descartes-08 For Myositis - Seeking Alpha
- 4 weeks ago - Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
- 2 months ago - Cartesian Therapeutics Announces New Employment Inducement Grant - GlobeNewsWire
- 2 months ago - Cartesian Therapeutics, Inc. (RNAC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 3 months ago - Cartesian Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Cartesian (RNAC) Q2 Revenue Drops 99% - The Motley Fool
- 6 months ago - Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis - GlobeNewsWire
- 7 months ago - Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire